TROV vs. QNCX, OKYO, AVRO, CYTH, DYAI, CDTX, GNTA, SABS, ENTX, and ESLA
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Quince Therapeutics (QNCX), OKYO Pharma (OKYO), AVROBIO (AVRO), Cyclo Therapeutics (CYTH), Dyadic International (DYAI), Cidara Therapeutics (CDTX), Genenta Science (GNTA), SAB Biotherapeutics (SABS), Entera Bio (ENTX), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector.
Cardiff Oncology (NASDAQ:TROV) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
Cardiff Oncology received 402 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
Cardiff Oncology has higher revenue and earnings than Quince Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
Quince Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Quince Therapeutics' return on equity of -36.36% beat Cardiff Oncology's return on equity.
10.0% of Cardiff Oncology shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by insiders. Comparatively, 21.0% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Quince Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Quince Therapeutics and 0 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.00 equaled Quince Therapeutics'average media sentiment score.
Summary
Quince Therapeutics beats Cardiff Oncology on 8 of the 12 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
